Nearly all neurodegenerative disease drug candidates fail. A more effective approach to drug development is urgently needed, but today’s AI efforts are falling short.
Fulcrum Neuroscience inverts the AI-biology playbook. Other platforms run a "find-then-rationalize" loop where a statistical method nominates a target, then a narrow hypothesis is built to defend it. Fulcrum builds a wide hypothesis first: a causal, dynamic model of human physiology written as differential equations across molecular, cellular, tissue, and population scales. Targets are outputs, not premises, and every candidate is ranked inside one framework rather than treated as an independent shot on goal.
The approach is rare because balancing equations to reconcile all available data within the same framework is uniquely demanding. The lineage is Quantitative Systems Pharmacology. QSP later narrowed inside pharma to "given this pathway, how do we dose this drug?" Fulcrum’s platform is the unconstrained modern form of the original QSP ambition, at the scale of the CNS multi-cell feedback architecture.
Fulcrum’s platform is unique in committing to homeostasis-first modeling, explicit feedback loops, structured uncertainty, human-genetic variability as ground truth, and targets-as-outputs.
This approach has allowed Fulcrum to formulate a new unified hypothesis of Alzheimer’s Disease, implicating cholesterol debris processing as a key progression driver upstream of amyloid and tau.
Fulcrum is developing proprietary Alzheimer’s therapeutics and new biomarkers derived from its unified hypothesis. We are also assisting in our partners’ programs by modeling disease progression, therapeutic effects, biomarkers, and clinical trials.
Platform
Science
Team
We are a multidisciplinary team with decades of experience in causal homeostatic modeling, systems biology, and AI software.
